Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Clinical trial NCT05651100 · UNKNOWN
Trial details
- NCT number
- NCT05651100
- Sponsor
- Kecellitics Biotech Company Ltd
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-10
- Primary completion
- 2024-12-10
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.